

1 **Psychological interventions for people with psychotic experiences: a systematic review**
2 **and meta-analysis of controlled and uncontrolled effectiveness and economic studies**

3
4 Emma Sonesson, MPhil* (Corresponding author; *joint first author;
5 es703@medschl.cam.ac.uk; Department of Psychiatry, University of Cambridge, Cambridge,
6 CB2 0SZ, UK)

7 Debra Russo, BSc Hons * (*Joint first author; dr335@medschl.cam.ac.uk; Department of
8 Psychiatry, University of Cambridge, Cambridge, CB2 0SZ, UK)

9 Jan Stochl, PhD (js883@cam.ac.uk; Department of Psychiatry, University of Cambridge,
10 Cambridge, CB2 0SZ, UK)

11 Margaret Heslin, PhD (margaret.heslin@kcl.ac.uk; King's College London, Institute of
12 Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, SE5 8AF, UK)

13 Julieta Galante, PhD (mjg231@medschl.cam.ac.uk; Department of Psychiatry, University of
14 Cambridge, Cambridge, CB2 0SZ, UK)

15 Clare Knight, BSc (ck462@medschl.cam.ac.uk; Department of Psychiatry, University of
16 Cambridge, Cambridge, CB2 0SZ, UK)

17 Nick Grey, DClinPsy (nick.grey@sussexpartnership.nhs.uk; Aldrington House, 35 New
18 Church Road, Hove, BN3 4AG, UK)

19 Joanne Hodgekins, PhD (j.hodgekins@uea.ac.uk; Department of Clinical Psychology,
20 Elizabeth Fry Building, Norwich Medical School, University of East Anglia, Norwich, NR4
21 7TJ, UK)

22 Paul French, PhD (paul.french@gmmh.nhs.uk; Psychosis Research Unit, Greater Manchester
23 Mental Health NHS Foundation Trust, Manchester, M25 3BL, UK)

24 David Fowler, MSc (d.fowler@sussex.ac.uk; School of Psychology, Pevensey Building,
25 University of Sussex, Brighton, BN1 9QH, UK)

26 Louise Lafortune, PhD (ll394@medschl.cam.ac.uk; Department of Public Health and Primary
27 Care, Cambridge Institute of Public Health, University of Cambridge, Cambridge, CB2 0SR,
28 UK)

29 Sarah Byford, PhD (s.byford@kcl.ac.uk; King's College London, Institute of Psychiatry,
30 Psychology & Neuroscience, De Crespigny Park, London, SE5 8AF, UK)

31 Peter B. Jones, PhD (pbj21@cam.ac.uk; Department of Psychiatry, University of Cambridge,
32 Cambridge, CB2 0SZ, UK)

33 Jesus Perez, PhD (jesus.perez@cpft.nhs.uk; Department of Psychiatry, University of
34 Cambridge, Cambridge, CB2 0SZ, UK)

35 **ABSTRACT**

36 **Objective.** Many people with psychotic experiences (PEs) do not develop psychotic
37 disorders, yet those who seek help demonstrate high clinical complexity and poor outcomes.
38 In this systematic review and meta-analysis, we evaluated the effectiveness and cost-
39 effectiveness of psychological interventions for people with PEs.

40 **Method.** We searched thirteen databases for studies of psychological interventions for adults
41 with PEs, but *not* psychotic disorders. Our outcomes were the proportion of participants
42 remitting from PEs (primary); changes in positive and negative psychotic symptoms,
43 depression, anxiety, functioning, distress, or quality of life; and economic outcomes
44 (secondary). We analysed results using multilevel random-effects meta-analysis and narrative
45 synthesis.

46 **Results.** Twenty-seven reports met inclusion criteria. In general, there was no strong
47 evidence for the superiority of any one intervention. Five studies reported on our primary
48 outcome, though only two reports provided randomised controlled trial evidence that
49 psychological intervention (specifically, cognitive behavioural therapy (CBT)) promoted
50 remission from PEs. For secondary outcomes, we could only meta-analyse trials of CBT. We
51 found that CBT was more effective than treatment as usual (TAU) for reducing distress
52 (pooled standardised mean difference: -0.24 [95% CI -0.37 to -0.10]), but no more effective
53 than the control treatment for improving any other outcome. Individual reports indicated that
54 CBT, mindfulness-based cognitive therapy, sleep CBT, systemic therapy, cognitive
55 remediation therapy, and supportive treatments improved at least one clinical or functional
56 outcome. Four reports included economic evaluations, which suggested CBT may be cost-
57 effective compared with TAU.

58 **Conclusions.** Our meta-analytic findings were primarily null, with the exception that CBT
59 may reduce the distress associated with PEs. Our analyses were limited by scarcity of studies,
60 small samples, and variable study quality. Several intervention frameworks showed
61 preliminary evidence of positive outcomes; however, the paucity of consistent evidence for
62 clinical and functional improvement highlights a need for further research into psychological
63 treatments for PEs.

64 **PROSPERO protocol registration number:** CRD42016033869

65

66 **Keywords:** psychosis, ultra-high risk, at-risk mental state, psychotic experiences,
67 psychological intervention

68

69 INTRODUCTION

70 High-risk criteria for psychotic disorders (Yung et al., 2003; Broome et al., 2005; Cannon et
71 al., 2008; Cornblatt et al., 2002; Miller et al., 2002; Yung et al., 1996) are predicated on the
72 presence of sub-threshold psychotic symptoms, also called psychotic experiences (PEs), and
73 the presumption that preventing or delaying transition to a full psychotic disorder syndrome
74 is a primary therapeutic target. However, most people with PEs never develop a psychotic
75 disorder (McGorry et al., 2018; Hui et al., 2013; Perez et al., 2017), but have high clinical
76 complexity, poor response to treatment (Perlis et al., 2011; Valiji Bharmal et al., 2015;
77 Wigman et al., 2014), sub-optimal clinical and functional outcomes, and increased risk of
78 self-harm (Fusar-Poli et al., 2012; Granö et al., 2011; Hui et al., 2013; Hutton et al., 2011;
79 Kelleher et al., 2012; Yates et al., 2019). Despite evidence of these poor outcomes, many
80 people with PEs do not meet the increasingly high thresholds for secondary care mental
81 health services, while in primary mental health care settings their PEs often go unnoticed or
82 untreated even though their depression and anxiety scores are higher, on average, than those
83 of individuals without PEs (Hui et al., 2013; Perez et al., 2017).

84

85 Research on psychological interventions for people with PEs has mainly focused on delaying
86 or preventing transition to psychotic disorder. Despite this focus, a recent network meta-
87 analysis of transition rates amongst people at high risk for psychosis found no evidence to
88 support the effectiveness of needs-based interventions, cognitive behavioural therapy (CBT),
89 integrated psychological interventions, or family-focused therapy in comparison with each
90 other (Davies et al., 2018a). A subsequent network meta-analysis of intervention effects
91 further found that no one specific intervention was more effective than others with regards to
92 reducing attenuated positive psychotic symptoms (Davies et al., 2018b). Yet, Nelson *et al.*
93 (2018) have proposed several limitations of these reviews, citing the omission of (1) trial
94 evidence demonstrating positive group-level effects of these interventions and (2) key clinical
95 (e.g. depression and general psychopathology) and functional outcomes that clearly have
96 important implications for the treatment of people with PEs (Nelson et al., 2018a).

97

98 Recent meta-analyses have left a number of key gaps concerning interventions for people
99 with PEs that must be filled in order to ensure that treatment decisions and clinical guidelines
100 are based on the most relevant, accurate, and up-to-date evidence available. First, most
101 reviews have limited their focus to ‘ultra-high risk’ or ‘clinical high risk’ populations, thereby
102 omitting people with PEs who may not have these diagnoses. Second, there is presently no

103 meta-analytic evidence addressing the question of which psychological interventions lead to
104 *remission* from PEs and improvement in depression, anxiety, and general functioning, all of
105 which are important features of at-risk states for psychosis that lead to disability (Byrne and
106 Morrison, 2014; Fowler et al., 2018; Law and Morrison, 2014). Third, the psychological
107 intervention that has been most investigated in the context of people with PEs is CBT, whilst
108 the evidence concerning alternative approaches has yet to be collated (Nelson et al., 2009).
109 Fourth, the cost-effectiveness of achieving therapeutic targets other than transition has
110 received little attention. Fifth, no review has set limitations for the use of antipsychotics,
111 despite the fact that international guidelines do not generally recommend their use for people
112 at-risk for developing psychosis (Addington et al., 2017; Early Psychosis Guidelines Writing
113 Group and EPPIC National Support Program, 2016; National Institute for Health and Care
114 Excellence, 2014b; Schmidt et al., 2015). Finally, no review has aimed to illuminate the key
115 ingredients of effective psychological interventions for this population. To address these
116 significant gaps in the literature and to inform the development of a new therapeutic
117 framework, we conducted a systematic review and meta-analysis that aimed to (1) synthesise
118 evidence about the effectiveness of and economic outcomes associated with psychological
119 interventions for people with PEs, and (2) identify common components of effective
120 interventions.

121

122 **METHODS**

123 This review was conducted as part of the *Tailoring evidence-based psychological therapy for*
124 *People with common mental disorder including Psychotic EXperiences* (TYPPEX), a
125 nationwide NIHR Programme Grant for Applied Research (RP-PG-0616-20003) that aims to
126 develop an effective therapeutic framework for service users with PEs in the UK Improving
127 Access to Psychological Therapies (IAPT) primary mental health care setting
128 (<https://www.england.nhs.uk/mental-health/adults/iapt/>). The programme focuses on clinical
129 and functional outcomes *other* than transition to psychotic disorder, reflecting the low
130 transition rate among individuals with PEs accessing primary mental health care services
131 (Hui et al., 2013; Perez et al., 2017). The therapeutic framework will adhere to current
132 international guidelines, which recommend psychological therapy – but *not* antipsychotic
133 medication – for the treatment of individuals with PEs (National Institute for Health and Care
134 Excellence, 2014a; Schmidt et al., 2015).

135

136 The protocol was registered with the International Prospective Register of Systematic
137 Reviews (PROSPERO; <https://www.crd.york.ac.uk/prospero>), registration number:
138 CRD42016033869 (22 May 2018 version), and a full protocol has been published
139 prospectively elsewhere (Soneson et al., 2019). We follow the PRISMA (Liberati et al., 2009)
140 reporting guidelines.

141

142 **Data sources and searches**

143 Two research assistants (ES & DR) collaborated with medical librarians at the University of
144 Cambridge to create the search strategy (Appendix A). The strategy combined terms for PEs,
145 specific psychotic symptoms, and psychological interventions, as well as database-specific
146 subject headings. We searched MEDLINE, Embase, and Health Management Information
147 Consortium (HMIC) via Ovid; PsycINFO, Cumulative Index to Nursing and Allied Health
148 Literature (CINAHL), Education Resources Information Center (ERIC), and EconLit via
149 EBSCO; British Nursing Index (BNI) via ProQuest; and all Cochrane databases from 1
150 January 2000 (or the earliest publication date included in the database, if after 2000) to 15
151 December 2018 (when we ran all searches). We additionally searched the WHO International
152 Clinical Trials Registry Platform (WHO ICTRP) for relevant trials and Google Scholar,
153 EThOS, and Open Grey for grey literature and dissertations. We collected additional citations
154 through hand-searching reference lists of included publications.

155

156 **Study selection**

157 We included studies that examined any psychological intervention in adults with PEs but *not*
158 psychotic disorders. To be included in our review, studies were required to have used the
159 presence of PEs as the main study entry criterion. Due to the variety of terms used to
160 represent PEs, we included populations with the following diagnoses: at-risk mental state,
161 ultra-high risk/clinical high risk, attenuated psychosis, psychosis-like experiences, unusual
162 experiences, sub-threshold psychosis, prodromal psychosis, and schizotypal disorders. We
163 restricted our studies to adults (operationalised as studies in which participants' mean age
164 was ≥ 16 years) to reflect the age of people attending adult mental health services (e.g. UK
165 IAPT services).

166

167 We included all frameworks of psychological interventions provided their effects were
168 studied *in people with PEs* (i.e. interventions did *not* need to target PEs specifically). We did
169 not restrict intervention setting (and included online interventions). We excluded studies that

170 combined psychological and pharmacological interventions (i.e. where medication was
171 provided *as part of the intervention protocol*). For medication prescribed *external to the*
172 *intervention*, we placed no restriction regarding the proportion of participants taking
173 medication for depressive or anxiety disorders, but included only studies in which less than
174 25% of participants were prescribed antipsychotic medication. The decision to limit the
175 proportion of the study population using antipsychotic medication aligns with international
176 guidelines' cautions against prescribing antipsychotics for people at high-risk for developing
177 psychosis (Addington et al., 2017; Early Psychosis Guidelines Writing Group and EPPIC
178 National Support Program, 2016; National Institute for Health and Care Excellence, 2014b;
179 Schmidt et al., 2015). This exclusion criterion further ensured the review was relevant to the
180 UK IAPT setting, where psychological interventions are the only available treatment.

181

182 Our outcomes of interest were (1) the proportion of participants who remitted from PEs
183 (primary outcome) and (2) changes in depression, anxiety, functioning, distress, quality of
184 life, or positive/negative psychotic symptoms (secondary outcomes). We placed no restriction
185 on which tools were used to measure any of these outcomes, so long as they were valid and
186 reliable. We did not set an *a priori* inclusion criterion for how to define remission from PEs
187 (we include in our results how each study defined/measured this outcome). In addition, we
188 included studies that reported any of the following economic outcomes: resource use, cost,
189 partial economic evaluations and full economic evaluations, where full economic evaluations
190 are those that consider both the cost and outcomes of two or more interventions in a
191 comparative analysis, whilst partial economic evaluations focus only on cost description,
192 cost-outcome description or comparative cost analysis (Drummond et al., 2015). Outcomes
193 did not need to be the primary outcome of a study to be included in our review.

194

195 We placed no restriction on study design or comparator. We chose not to limit our review to
196 controlled trials in order to ensure that newer intervention frameworks (which may be at pilot
197 or earlier stages) could be represented.

198

199 We reviewed studies published in any language provided they had an English abstract (no
200 foreign language articles advanced past the title/abstract screening stage). We excluded
201 reports published before 2000 (when the at-risk mental state became widely adopted), reports
202 where only an abstract was available, and secondary analyses of data from the same trial (to
203 avoid including the same data from one individual multiple times within our results).

204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237

Two reviewers (ES & DR) independently screened titles and abstracts and excluded obviously irrelevant titles. We then reviewed the full texts of potentially relevant citations against our inclusion and exclusion criteria. Disagreements were resolved by discussion, with input from a third reviewer (CK, JP) as necessary.

Data extraction and quality appraisal

Three reviewers (ES, DR, MH) designed and piloted data extraction sheets. We extracted information on study/sample characteristics, intervention components and descriptions, data for outcomes related to our primary or secondary outcomes, and data required for quality assessment (see protocol for more detail (Soneson et al., 2019)). Where information was not available, we consulted study protocols and contacted study authors by email. Two reviewers independently extracted data from a subset of four papers (17%) and one reviewer extracted the rest. Both reviewers reviewed all quantitative data for each included study.

We assessed risk of bias using the Effective Public Health Practice Project's (EPHPP) Quality Assessment Tool for Quantitative Studies (Armijo-Olivo et al., 2012) for all reports and additionally used the Drummond Critical Appraisal of Economic Evaluations Checklist (Drummond and Jefferson, 1996) for economic reports. Two raters (ES & DR; MH & SB for economic studies) independently assessed quality, compared ratings, and resolved disagreements by discussion.

Data synthesis and analysis

Meta-analysis

We analysed controlled studies through random-effects meta-analysis of standardised mean differences (SMDs) for our secondary clinical and functional outcomes (we did not have sufficient reports to perform meta-analysis for our primary outcome; see below). To combine outcomes from multiple follow-up points within individual reports, we fitted meta-analytic multilevel random effects models via functions in the *metafor* package (Viechtbauer, 2010). A relatively new methodology, multilevel meta-analysis is becoming popular in the literature (Fernández-Castilla et al., 2019). The model overcomes the possibility of bias of overall effect by acknowledging that different time-points are not independent and correcting for this.

238 Ultimately, we conducted seven separate meta-analyses (one for each secondary outcome),
239 separating each by the framework of the psychological intervention being investigated (as per
240 protocol (Soneson et al., 2019)). As CBT was the only intervention to be represented in more
241 than one study, we were not able to conduct meta-analyses for the other intervention
242 frameworks included in the review.

243

244 We separated results by comparator framework (supportive treatments (ST) vs. treatment as
245 usual (TAU)). We classified the following interventions as ST: supportive therapy,
246 supportive counselling, non-directive reflective listening, needs-based intervention, and
247 needs-focused intervention. The decision to group these interventions was based on
248 similarities in their purpose and provision. We considered these interventions to have a
249 common aim, namely, to act as non-specific active comparison groups. They further share
250 several characteristics (e.g. warm, empathic listening and absence of active therapeutic
251 techniques). This classification also facilitates comparison with related reviews that used
252 similar groupings (Davies et al., 2018a; Davies et al., 2018b). In reporting our results, we
253 provide separate pooled estimates for each comparator framework (i.e. ST and TAU
254 separately) as well as an estimate for both comparators combined (i.e. ST and TAU
255 combined). There are clinical and statistical reasons for this decision. First, the difference
256 between TAU and ST is not well-defined; for example, ‘treatment as usual’ sometimes
257 consisted of CBT for depression or anxiety. Second, we found no statistical evidence to
258 indicate any meaningful difference between outcomes for these comparators. As both
259 interpretations are valid, and to ensure our results can adequately inform clinical practice, we
260 include both estimates.

261

262 *Sensitivity and subgroup analyses*

263 We also conducted sensitivity analyses by including only those reports that received a global
264 rating of ‘strong’ on the EPHPP tool.

265

266 No controlled clinical trials (CCTs) met inclusion criteria, and so our planned sensitivity
267 analysis on the impact of CCTs was not possible. We had also intended to conduct subgroup
268 analyses based on population (clinical vs. non-clinical), but no studies of non-clinical
269 populations were eligible for inclusion in the meta-analyses. Finally, we had intended to use
270 sub-group analyses to quantitatively assess four *a priori* components of interest for cognitive
271 therapy as previously highlighted in the literature: assessment of problems and goals,

272 formulation, homework, and active change strategies (Flach et al., 2015; Morrison and
273 Barratt, 2009). However, included reports did not meet our pre-specified criteria for sub-
274 group analyses (see protocol for more detail (Soneson et al., 2019)).

275

276 *Assessment of heterogeneity and meta-biases*

277 Although we aimed to assess heterogeneity of the meta-analytic results, this was unreliable
278 due to low numbers of included reports in each meta-analysis (Deeks et al., 2018). We still
279 report Cochran's Q for each meta-analysis, but interpretation needs to be cautious. For the
280 same reason, it was not possible to perform the assessments of bias (e.g. publication bias,
281 citation bias) specified in our protocol.

282

283 *Narrative synthesis*

284 We use narrative synthesis (Popay et al., 2006) to synthesise effectiveness findings and pre-
285 post changes in our outcomes of interest from (1) controlled studies not eligible for inclusion
286 in the meta-analyses, and (2) uncontrolled studies. We furthermore narratively describe
287 findings relating to common components of effective therapies.

288

289 *Economic analysis*

290 We present economic studies in tables containing study characteristics and results and use a
291 narrative approach to synthesise findings as a result of the very small number of identified
292 studies meeting inclusion criteria for the economic component of the review. We further
293 discuss reports in terms of quality, using the Drummond checklist (Drummond et al., 2015).

294

295 **RESULTS**

296 *Search results*

297

298 ****Insert Fig 1 about here****

299 Figure 1. PRISMA flowchart (Liberati et al., 2009)

300

301 We identified 27 reports from 21 studies that met inclusion criteria (flowchart in Figure 1;
302 summary of studies' characteristics in Table 1; justifications for exclusion after full-text
303 screening in Appendix B; summary of baseline and outcome data in Appendix C;
304 intervention components in Appendix D). Of these 27 reports, four reports using data from
305 two randomised controlled trials (RCTs) included economic components that met our

306 inclusion criteria. The interventions had diverse frameworks; while the vast majority of
307 studies focused on variations on CBT or ST (always as the comparator), one study each
308 represented strengths and mindfulness-based online social therapy, sleep CBT, mindfulness-
309 based cognitive therapy, family-focused therapy, family psycho-educational intervention,
310 cognitive remediation, and systemic therapy (each described below). The majority of these
311 frameworks have been tested in the past five years, suggesting increased interest in new
312 intervention frameworks for people with PEs.

313

314 **CBT.** CBT for PEs (and other therapies where CBT is the key component, e.g. integrated
315 psychological interventions) (Addington et al., 2011; Bechdolf et al., 2005; Bechdolf et al.,
316 2007; Evans et al., 2017; Ising et al., 2016; Ising et al., 2017; Ising et al., 2015; Kommescher
317 et al., 2016; Matsumoto et al., 2018; McGorry et al., 2017; McGorry et al., 2013; Morrison et
318 al., 2012; Morrison et al., 2004; Nelson et al., 2018b; Stafford et al., 2015; Stain et al., 2016;
319 van der Gaag et al., 2012) explore the links between thoughts, emotions, and behaviour. The
320 therapy is formulation-driven, problem-oriented, time-limited, and tailored to patients' needs.
321 The key components include patient engagement, creation of a mutually-agreed problem list,
322 formulation, normalisation of PEs and patients' interpretations of them, evaluation of
323 alternative explanations, and behavioural experiments to challenge patients' appraisals of
324 PEs.

325

326 **Cognitive remediation.** Cognitive remediation refers to behavioural training aimed at
327 improving cognitive processes (e.g. attention, memory, and executive function) (Barlati et al.,
328 2013). The cognitive remediation intervention included in this review focuses on improving
329 auditory processing in people with PEs (Piskulic et al., 2015). It is computer-based and
330 includes several different exercises aimed to improve the diverse aspects of auditory
331 processing.

332

333 **Family-focused therapy.** This therapy (O'Brien et al., 2015) treats people with PEs in the
334 context of the family. The key components include psychoeducation around topics such as
335 symptoms, daily stressors, coping strategies, the vulnerability-stress perspective, family
336 support, and prevention action plans. Family members learn a structured approach to defining
337 problems, breaking down complex problems, brainstorming solutions, analysing pros and
338 cons of possible solutions, and selecting and implementing action plans.

339

340 **Family psychoeducational intervention.** The included family psychoeducational intervention
341 (O'Brien et al., 2015) was a brief, 3-session process of providing education and information.
342 The content mirrored that of the psychoeducation aspect of the family-focused therapy
343 described above.

344

345 **Mindfulness-based cognitive therapy (MBCT).** Mindfulness-based cognitive therapy
346 (Langer et al., 2010) includes psychoeducation and exercises to demonstrate the links
347 between thinking and feeling. Specific techniques include 'Body Scan' training, mindful
348 breathing, breathing space, yoga, and sitting meditation. The intervention uses a group-based
349 format.

350

351 **Sleep CBT.** The sleep CBT included this review (Bradley et al., 2017) used the 'SleepWell'
352 treatment package, which utilises CBT techniques to address insomnia and circadian rhythm
353 disruption to reduce sleep disturbances. Therapists use individualised formulation of sleep
354 problems to identify treatment targets and actigraphy data to monitor changes in sleep
355 patterns and highlight potential areas for change.

356

357 **Strengths and mindfulness-based online social therapy.** This intervention, set within a
358 social media context, takes a strengths and mindfulness-based focus, and uses a self-
359 determination theory of motivation to foster self-efficacy and increase positive emotions
360 (Alvarez-Jimenez et al., 2018). The intervention provides social 'online' support moderated
361 by expert and peer moderators. Modules addressed personal strengths, mindfulness,
362 connecting with others, and group problem-solving to promote self-efficacy and interpersonal
363 problem-solving.

364

365 **Systemic therapy.** Systemic therapy (Shi et al., 2017) is centred around systemic-
366 constructivist and psychosocial resilience theories. The therapy focuses on solutions and
367 resources, and encourages patients to reframe their problems and better understand their
368 available resources in order to solve these problems.

369

370 **Supportive treatments.** As stated above, the category of supportive treatments includes
371 supportive therapy, supportive counselling, non-directive reflective listening, needs-based
372 intervention, and needs-focused intervention (Addington et al., 2011; Bechdolf et al., 2007;
373 Kommescher et al., 2016; McGorry et al., 2013; Stain et al., 2016; Shi et al., 2017; Phillips et

374 al., 2007; Ruhrmann et al., 2007). In general, these interventions are use general counselling
375 techniques, including warm, empathic, and non-judgmental face-to-face contact and
376 supportive listening. They do not include active therapeutic techniques.

377

378 ****Insert Table 1 about here****

379 Table 1. Summary of studies included in the clinical effectiveness component of the review

380

381 The quality of included studies was mixed (Table 2); 21 of the 27 reports used a randomised
382 controlled trial (RCT) design, of which only four received a global rating of ‘strong,’ ten
383 received a global rating of ‘moderate,’ and seven received a global rating of ‘weak.’ Selection
384 bias, confounding, and drop-out were the categories that most limited the global ratings (it
385 should be noted that a rating of ‘strong’ in the selection bias category is not achievable when
386 only help-seeking patients are included. Importantly, no study was excluded in the sensitivity
387 analyses based solely on studying a help-seeking population). The remaining four studies
388 used a pre-post design – relatively, a much weaker study design – but none of these received
389 a ‘weak’ rating in any of the applicable categories.

390

391 ****Insert Table 2 about here****

392 Table 2. Quality of included studies (EPHPP rating tool)

393

394 **Primary outcome**

395 Five reports from four studies provided the proportion of participants that remitted from PEs
396 following psychological intervention (Ising et al., 2016; Matsumoto et al., 2018; Ruhrmann et
397 al., 2007; Shi et al., 2017; van der Gaag et al., 2012). Meta-analysis was not possible for the
398 primary outcome: only two reports had the same intervention framework and comparator
399 category, and the more recent was a follow-up of the first (van der Gaag et al., 2012; Ising et
400 al., 2016).

401

402 **CBT.** Both studies of CBT used the CAARMS (Yung et al., 2005) to determine remission
403 status. In an RCT examining differences between CBT + TAU versus TAU, 70.4% of
404 participants receiving CBT + TAU had remitted from at-risk mental state (ARMS) status by
405 12 months post-intervention, as compared with 57.0% of participants receiving TAU only
406 (p=0.039) (van der Gaag et al., 2012). The difference remained significant at medium-term
407 follow-up (approximately 3.5 years post-therapy), with 76.3% of CBT + TAU group versus

408 58.7% of TAU only in remission ($p=0.04$) (Ising et al., 2016). A pre-post study of CBT found
409 ARMS remission rates of 46.2% at post-intervention and 84.6% 6 months post-intervention
410 (Matsumoto et al., 2018).

411

412 **Other frameworks.** An RCT comparing systemic therapy with supportive therapy found
413 greater remission from clinical high risk status (measured using the Scale of Prodromal
414 Symptoms (Miller et al., 2003)) among those receiving systemic therapy (61.5% versus
415 46.2%), but the difference was not significant ($p=0.431$) (Shi et al., 2017). Finally, a trial of a
416 needs-focused intervention found a 20.5% remission rate from all psychotic symptoms
417 (assessed with the Early Recognition Inventory – Positive Psychosis Spectrum (ERI-PPS)
418 (Klosterkötter et al., 2001)) at post-therapy (Ruhrmann et al., 2007).

419

420 **Secondary outcomes**

421 As mentioned above, we were only able to include studies of CBT in our meta-analyses, as
422 CBT was the only framework examined in two or more studies.

423

424 ****Insert Figure 2 about here****

425 **Figure 2.** Positive psychotic symptoms: meta-analysis summary plot (NB: follow-up times are measured from
426 the end of the intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive
427 treatments.

428

429 ****Insert Figure 3 about here****

430 **Figure 3.** Negative psychotic symptoms: meta-analysis summary plot (NB: follow-up times are measured from
431 the end of the intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive
432 treatments.

433

434 ****Insert Figure 4 about here****

435 **Figure 4.** Distress: meta-analysis summary plot (NB: follow-up times are measured from the end of the
436 intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.

437

438 ****Insert Figure 5 about here****

439 **Figure 5.** Depression: meta-analysis summary plot (NB: follow-up times are measured from the end of the
440 intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.

441

442 ****Insert Figure 6 about here****

443 **Figure 6.** Anxiety: meta-analysis summary plot (NB: follow-up times are measured from the end of the
444 intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.
445

446 ****Insert Figure 7 about here****

447 **Figure 7.** Functioning: meta-analysis summary plot (NB: follow-up times are measured from the end of the
448 intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.
449

450 ****Insert Figure 8 about here****

451 **Figure 8.** Quality of life: meta-analysis summary plot (NB: follow-up times are measured from the end of the
452 intervention). CBT: cognitive behavioural therapy; TAU: treatment as usual; ST: supportive treatments.
453

454 **CBT.** We included eight reports from seven studies in our meta-analyses (Figures 2-8), four
455 of which compared CBT (with or without TAU) with TAU only. CBT was superior to TAU
456 in reducing distress (pooled SMD = -0.24 favouring CBT [95% CI -0.37 to -0.10]). No other
457 statistically significant differences were found for positive psychotic symptoms (pooled SMD
458 = -0.14 favouring CBT [-0.32 to 0.04]), depression (pooled SMD = -0.15 favouring CBT [-
459 0.35 to 0.06]), anxiety (pooled SMD = -0.02 favouring CBT [-0.22 to 0.18]), functioning
460 (pooled SMD = -0.09 favouring TAU [-0.22 to 0.04]), or quality of life (pooled SMD = -0.03
461 favouring TAU [-0.24 to 0.18]).

462
463 Four additional reports compared CBT with a supportive treatment (ST; e.g. supportive
464 therapy, supportive counselling, or non-directive reflective listening). No statistically
465 significant differences were found for positive psychotic symptoms (pooled SMD = -0.12
466 favouring CBT [-0.61 to 0.38]), negative psychotic symptoms (pooled SMD = 0.14 favouring
467 ST [-0.30 to 0.57]), depression (pooled SMD = 0.09 favouring ST [-0.33 to 0.52]), anxiety
468 (pooled SMD = -0.18 favouring CBT [-0.71 to 0.34]), or functioning (pooled SMD = -0.15
469 favouring CBT [-0.29 to 0.59]).

470
471 To determine whether there was a difference between the two different control groups, we
472 included TAU and ST as predictors of SMD in a meta-regression model. Because there was
473 not a statistically significant difference between the different control groups for any outcome,
474 we also computed a pooled estimate for all reports regardless of comparator. When TAU and
475 ST were collapsed into a single comparator group, CBT remained more effective than the
476 combined TAU/ST comparison groups at reducing distress (pooled SMD: -0.23 favouring

477 CBT [-0.36 to -0.10]). There were no other statistically significant differences between CBT
478 and controls.

479

480 Two reports found significant between-group differences in severity of psychotic symptoms
481 in two distinct trials, in each instance favouring cognitive therapy ($p=0.049$ and $p=0.018$,
482 respectively) (Morrison et al., 2012; Morrison et al., 2004). A further two reports found
483 significant between-group differences in distress, but in opposite directions: while one found
484 lower distress amongst participants in the CBT group ($p=0.012$) (van der Gaag et al., 2012),
485 the other found lower distress amongst participants in the non-directive reflective listening
486 (ST) group ($p=0.029$) (Stain et al., 2016). No RCT found any statistically significant
487 between-group differences for depression, anxiety, functioning, or quality of life.

488

489 Additionally, reports from three controlled (Addington et al., 2011; Bechdolf et al., 2007;
490 McGorry et al., 2017) and four uncontrolled studies (Bechdolf et al., 2005; Evans et al., 2017;
491 Matsumoto et al., 2018; Stafford et al., 2015) provided results of significance tests for within-
492 group pre-post changes for individuals receiving CBT (several more noted symptom
493 improvement, but did not provide formal significance testing results). The three reports
494 providing data on positive psychotic symptoms (Addington et al., 2011; Matsumoto et al.,
495 2018; Stafford et al., 2015), and one of three providing data on negative psychotic symptoms
496 (McGorry et al., 2017) found significant improvement. Significant improvement was also
497 noted in four of five reports providing data on depression (Bechdolf et al., 2005; Evans et al.,
498 2017; Matsumoto et al., 2018; McGorry et al., 2017) and functioning (Bechdolf et al., 2005;
499 Bechdolf et al., 2007; Matsumoto et al., 2018; McGorry et al., 2017), all four reports
500 providing data on anxiety (Addington et al., 2011; Bechdolf et al., 2005; Evans et al., 2017;
501 Matsumoto et al., 2018), one of two providing data on distress (Evans et al., 2017), and in the
502 one report that provided data on quality of life (Matsumoto et al., 2018). No study found
503 statistically significant decline in any domain.

504

505 **Supportive treatments.** Reports from five controlled studies (Addington et al., 2011;
506 Bechdolf et al., 2007; Phillips et al., 2007; Ruhrmann et al., 2007; Shi et al., 2017) provided
507 results from significance testing for within-group pre-post changes for individuals receiving
508 supportive or needs-focused treatments. Two of four reports providing data on positive
509 psychotic symptoms (Addington et al., 2011; Ruhrmann et al., 2007), but none of the four
510 providing data on negative psychotic symptoms found significant improvement. Significant

511 improvement was noted in two of four reports providing data on depression (Addington et al.,
512 2011; Ruhrmann et al., 2007), one of two providing data on anxiety (Addington et al., 2011),
513 one of five providing data on functioning (Bechdolf et al., 2007), and in the one report
514 providing data on in quality of life (Phillips et al., 2007). No study found statistically
515 significant decline in any domain.

516

517 ***Other intervention frameworks.*** Four additional RCTs focused on the systemic therapy (Shi
518 et al., 2017), mindfulness-based cognitive therapy (MBCT) (Langer et al., 2010), family-
519 focused therapy (FFT) (O'Brien et al., 2015), and cognitive remediation therapy (CRT)
520 (Piskulic et al., 2015). Only the MBCT trial showed any between-group differences in our
521 outcomes of interest. In this study, MBCT was more effective than the control condition (a
522 video viewing forum) at reducing anxiety from baseline to post-therapy ($d=0.88$, $p=0.012$) as
523 well as baseline to 12-week follow-up ($d=0.91$, $p=0.048$). However, we found no other
524 significant between-group differences for psychotic symptoms or distress (Langer et al.,
525 2010).

526

527 Systemic therapy, CRT, and FFT were no more effective than their control treatments
528 (supportive therapy, computer games, and family psychoeducation, respectively) (Shi et al.,
529 2017; Piskulic et al., 2015; O'Brien et al., 2015). Although neither systemic therapy nor CRT
530 was more effective than its control treatment, each showed within-group pre-post effects.
531 Individuals who received systemic therapy showed significant reductions in positive
532 symptoms ($d=0.53$, $p=0.005$) and depressive symptoms ($d=0.75$, $p=0.010$) from baseline to
533 post-therapy, while no such changes were found for the supportive therapy group.(Shi et al.,
534 2017) Similarly, individuals assigned to CRT had significant improvements in social
535 functioning ($p<0.05$) from baseline to 6 months post-intervention, while those assigned to the
536 computer games condition had no significant improvements (Piskulic et al., 2015).

537 A further two uncontrolled studies examined within-group pre-post effects of a strengths and
538 mindfulness-based online social therapy (Alvarez-Jimenez et al., 2018) and a CBT
539 intervention for sleep problems (Bradley et al., 2017). The former found significant
540 improvements in social functioning ($d=1.83$, $p<0.001$) from baseline to post-intervention
541 (Alvarez-Jimenez et al., 2018), and the latter found significant improvements in depression
542 and quality of life ($p<0.05$; exact values not given). These improvements were maintained at
543 1-month post-therapy, at which time improvement in paranoia and hallucinations also
544 reached significance ($p<0.05$; exact values not given) (Bradley et al., 2017).

545 Most of the meta-analyses described in this section suffered from high heterogeneity
546 (Cochran's Q $p < 0.05$). However, this measure is unreliable when the number of studies
547 included is very low, so although heterogeneity cannot be discarded, it is hard to ascertain its
548 extent.

549

550 ***Sub-group analyses***

551 For sub-group analyses by quality, we were only able to perform two meta-analyses (for
552 functioning and positive symptoms) due to the fact that in all other meta-analyses there was
553 only one study without a high risk of bias in at least one category. We found no statistically
554 significant difference between CBT and TAU in either subgroup analysis (see Appendix E).

555

556 ***Components of effective interventions***

557 We focused our components analysis on the five interventions that showed effectiveness for
558 at least one outcome *in controlled trials*: three CBT (Morrison et al., 2012; Morrison et al.,
559 2004; van der Gaag et al., 2012), one mindfulness-based cognitive therapy (Langer et al.,
560 2010), and one non-directive reflective listening intervention (Stain et al., 2016) (intervention
561 components in Appendix D). Qualitative examination of the components of these five
562 therapies revealed high heterogeneity: very few components were shared across the effective
563 therapies, which is unsurprising given their differing frameworks. Furthermore, there were no
564 'key ingredients' that were particular to these five therapies: although there were some
565 common components across the effective therapies (e.g. mode of delivery), these were also
566 shared by therapies that did not demonstrate effectiveness.

567

568 ***Economic studies***

569 Four reports met inclusion criteria for the economic component of the review (summary of
570 studies' characteristics in Appendix F; quality assessment in Appendix G; full economic
571 analysis in Appendix H). Two focused on CBT (Ising et al., 2017; Ising et al., 2015) and two
572 on ST (Phillips et al., 2009; Phillips et al., 2007).

573

574 ***CBT.*** Ising and colleagues reported the results of full economic evaluations in two reports
575 (Ising et al., 2017; Ising et al., 2015), which were based on 18-month and 4-year post-
576 baseline data, respectively, from a study conducted in the Netherlands between 2008 to 2010
577 comparing routine care plus CBT for the prevention of psychosis with routine care alone for
578 individuals at ultra-high risk of psychosis aged 14 to 35 years old (Rietdijk et al., 2010). At

579 18-months post-baseline, the authors concluded that CBT proved to be cost-saving, however,
580 differences in costs between groups were not tested statistically. When combined with
581 outcome data, there was some evidence to suggest that CBT plus routine care may be cost-
582 effective compared to routine care alone, but differences were small and no assessment of
583 uncertainty was carried out. Results were clearer at 4-years post-baseline, with evidence to
584 suggest a high probability (>80%) of the CBT group being cost-effective compared to routine
585 care alone.

586

587 **Supportive treatments.** Phillips and colleagues (Phillips et al., 2009; Phillips et al., 2007)
588 explored resource use and cost-savings in two reports, both based on data from an RCT
589 conducted in Australia between 1996 and 1999 which compared a needs-based intervention
590 (NBI) with NBI plus a specific preventive intervention (SPI) including psychotherapy and
591 neuroleptic medication for individuals aged 14 to 30 at ultra-high risk of developing
592 psychotic disorder (McGorry et al., 2002). In the first paper (Phillips et al., 2007), the authors
593 explored resource use from a mental health service perspective between 12 and 36 months
594 post-randomisation. Resource use was reported by group for some resource items and by
595 those who did or did not develop psychosis for others. There was little difference in resource
596 use with the exception of significantly higher mental health service use for those who did not
597 develop psychosis in the control arm. However, sample sizes were small (total n=41) and cost
598 differences were not tested statistically. In the second paper,(Phillips et al., 2009) a cost-
599 savings analysis was undertaken for the full 36-month post-baseline follow-up period. There
600 were no significant differences in total cost between the groups over the full follow-up. In
601 terms of outcomes (Phillips et al., 2007), no differences in transition to psychosis rates, level
602 of symptomatology, or functioning between the groups were identified, therefore indicating
603 there may be no cost-effectiveness advantage of the intervention.

604

605 **DISCUSSION**

606 This systematic review and meta-analysis included 27 reports concerning 21 studies of
607 psychological interventions for PEs and aimed to determine their effectiveness and cost-
608 effectiveness for improving a range of clinical and functional outcomes. In terms of the
609 proportion of participants remitting from PEs, we found preliminary evidence from one RCT
610 and one uncontrolled study for the potential effectiveness of CBT. We did not find meta-
611 analytic evidence that CBT improved PEs on a continuous scale, though it is likely that our
612 analyses were underpowered to detect small effects. Whilst two individual RCTs favoured

613 CBT over TAU for reducing the severity of psychotic symptoms, this effect was not
614 consistent across all controlled studies. CBT, sleep CBT, and systemic therapy – but not
615 supportive treatments – also showed promise in terms of within-group pre-post improvements
616 in psychotic symptoms.

617

618 For our other non-psychotic secondary outcomes (depression, anxiety, functioning, distress,
619 and quality of life), only the meta-analysis of distress outcomes revealed evidence of
620 comparative effectiveness, by which CBT was more effective than comparators. However, a
621 high degree of heterogeneity cannot be discarded in this meta-analysis, meaning that CBT
622 may not reduce distress in all implementation scenarios in this patient population. Two
623 individual trials showed a significant effect on distress, but in opposite directions. The only
624 other RCT evidence of effectiveness was for mindfulness CBT, which significantly reduced
625 participants' anxiety symptoms. Low quality evidence from uncontrolled studies showed that
626 a number of therapies were effective for at least one non-psychotic clinical or functional
627 outcome, including CBT, sleep CBT, systemic therapy, CRT, and mindfulness online social
628 therapy. Supportive treatments were fairly effective at improving anxiety and depression, but
629 not other outcomes.

630

631 The overall quality of studies included in the effectiveness component of the review was
632 variable. Whilst most reports (21 of 27) focused on data from RCTs (the gold standard study
633 design for investigating intervention effect), all but four of these received a rating indicating
634 high risk of bias in at least one of the rating categories. High rates attrition were the
635 predominant reason for lower ratings, followed by high chance of selection bias. The six non-
636 randomised, uncontrolled studies, although prone to the significant biases associated with
637 lower quality study design, did not receive any rating indicating high risk of bias in any other
638 applicable category (these were not rated in terms of blinding or confounders).

639

640 Economic data meeting the inclusion criteria were only identified in four publications, which
641 used data from two RCTs, one focusing on CBT and the other focusing on a specific
642 preventive intervention which included psychotherapy and antipsychotic medication. Both
643 interventions were targeted at young adults at ultra-high risk of psychosis. No economic data
644 were identified for any other interventions. The included economic studies were
645 methodologically strong, meeting most of the Drummond checklist quality assessment
646 criteria (Drummond and Jefferson, 1996). The economic studies focusing on CBT indicate

647 that the addition of CBT to routine care has a high probability of being cost-effective
648 compared to routine care alone in this ultra-high risk group.

649
650 Several previous systematic reviews and meta-analyses have examined the effectiveness of
651 psychological, pharmacological, and nutritional interventions for people with PEs. Although
652 most reviews focused primarily on transition (and four focused exclusively on transition),
653 seven (Davies et al., 2018b; Hutton and Taylor, 2014; Marshall and Rathbone, 2011;
654 Okuzawa et al., 2014; Stafford et al., 2013; van der Gaag et al., 2013; Devoe et al., 2019) also
655 reported selected secondary outcomes that do correspond with the current review's focus,
656 specifically psychotic symptoms (Davies et al., 2018b; Marshall and Rathbone, 2011;
657 Okuzawa et al., 2014; Stafford et al., 2013; Devoe et al., 2019), distress (Hutton and Taylor,
658 2014; Okuzawa et al., 2014), depression (Marshall and Rathbone, 2011; Okuzawa et al.,
659 2014; Stafford et al., 2013), anxiety (Marshall and Rathbone, 2011; Okuzawa et al., 2014),
660 functioning (Hutton and Taylor, 2014; Marshall and Rathbone, 2011; Okuzawa et al., 2014;
661 van der Gaag et al., 2013), and quality of life (Hutton and Taylor, 2014; Marshall and
662 Rathbone, 2011; Okuzawa et al., 2014; Stafford et al., 2013). Importantly, no prior review
663 has included a consideration of remission from PEs. None of these reviews (including the
664 review upon which current UK clinical guidelines are based) has found strong evidence to
665 support the effectiveness of any particular psychological intervention for improving our
666 outcomes of interest within this population. In general, these reviews reflect our own results.
667 However, departing from previous findings, we found meta-analytic evidence that distress
668 was significantly reduced after CBT compared with control treatments (TAU/ST). It is
669 possible that distress is a significant, under-measured, and under-reported outcome in the
670 literature; indeed, only two previous reviews have reported distress as an outcome. Distress is
671 an important factor to individuals with PEs as reductions can be interpreted as improvement,
672 despite residual symptoms (Byrne and Morrison, 2014; Fowler et al., 2018; Law and
673 Morrison, 2014); consequently, a broader consideration of this outcome is warranted.

674 Major treatment guidelines currently recommend CBT for the treatment of people at-risk for
675 developing psychosis (Addington et al., 2017; Early Psychosis Guidelines Writing Group and
676 EPPIC National Support Program, 2016; National Institute for Health and Care Excellence,
677 2014b; Schmidt et al., 2015). In the UK, the National Institute for Health and Care
678 Excellence (NICE) highlights the value of CBT for preventing transition to frank psychotic
679 disorder (National Institute for Health and Care Excellence, 2014a). However, recent meta-

680 analytic evidence published since the creation of these guidelines suggests that CBT for
681 populations at-risk for developing psychosis may not be superior to other interventions in
682 preventing transition (Davies et al., 2018a), although it is important to note that concerns
683 have been raised about both the methodology and interpretation of results in this review
684 (Nelson et al., 2018a). Our findings provide initial evidence that, whilst doubts remain about
685 its effectiveness in terms of preventing transition to psychosis, CBT may nevertheless be
686 more effective than other approaches at promoting *remission* from PEs and reduction of
687 associated distress, and thus may still be considered as a potentially useful intervention for
688 treating people with PEs. Conversely, when the aim of psychological intervention is to reduce
689 other clinical symptoms (e.g. depression and anxiety) or functional impairment associated
690 with PEs, CBT falls short in demonstrating effectiveness as compared with other treatments.
691 This is an important shortcoming, as poor clinical and functional outcomes may serve to
692 perpetuate mental ill health that may still require more than just monitoring for changes in
693 post-CBT persistent symptoms, as currently recommended by NICE (National Institute for
694 Health and Care Excellence, 2014a).

695

696 **Strengths and Limitations**

697 This review has a number of important strengths and addresses key gaps in the literature
698 concerning psychological interventions for people with PEs. Specifically, to our knowledge,
699 we were the first to meta-analyse studies across such a broad range of clinical and functional
700 outcomes. Second, we focus on remission from PEs, a new and important outcome that was
701 developed in collaboration with our lived experience advisory panel. Third, we include
702 economic outcomes, which again have not been reviewed previously. Fourth, we review a
703 large number of studies not included in any other review, including, importantly, studies of
704 newer, non-CBT frameworks

705

706 These strengths notwithstanding, our review, and in particular our meta-analyses, has a
707 number of limitations. First, each meta-analysis included a small number of reports, each of
708 which had a limited number of participants (sometimes short of the recruitment target). This
709 will have reduced our power to detect small, but potentially clinically meaningful, treatment
710 effects. We aimed to increase power by including multiple study follow-up points within each
711 meta-analysis. Although we could also have combined outcomes to reduce the total number
712 of meta-analyses (and also the probability of type I error), we chose not to do this as (1)
713 sometimes outcomes changed in different directions following intervention (for an example,

714 see Langer *et al.* (2010)), and (2) Cochrane warns against combining heterogeneous
715 outcomes (see Section 9.1.4) (Higgins and Green, 2011). Second, the high number of meta-
716 analyses performed will have increased the probability of false positive results, which is
717 particularly important in our analyses due to the fact that we found only one significant
718 effect. Third, we could not rule out high heterogeneity within our meta-analyses. Fourth, our
719 decision to group several therapy types under ‘supportive therapy’ was not without
720 limitations; for example, patients under TAU conditions may well receive CBT for other
721 mental health problems outside of PEs (e.g. depression or anxiety). Fifth, our exclusion
722 criteria regarding age range and antipsychotic use may limit the generalisability of our
723 findings to younger populations or patients prescribed antipsychotic medication as part of
724 their treatment plan. Sixth, in terms of the studies themselves, whilst many utilised
725 randomised controlled designs, the overall methodological quality was not high; only four
726 studies received a global rating of ‘high’ on the quality rating tool. Finally, we acknowledge
727 that we were not able to fulfill all *a priori* review aims. Whilst the review was ambitious, we
728 contend that it was not possible to predict which aims could and could not be accomplished.
729 Furthermore, we believe that highlighting gaps in the literature is an important step in moving
730 the field forward.

731

732 **Conclusions**

733 This review has clear clinical relevance and will be central in the development of a new
734 therapeutic framework for IAPT, as well as for other programmes aiming to address PEs in
735 primary mental health care settings internationally. The broad aims, comprehensive
736 outcomes, and specific selection criteria all reflect this purpose. The review will ensure any
737 decisions concerning treatment development and treatment selection for people with PEs
738 within primary care are supported by the most recent and high-quality evidence. Overall, our
739 findings indicate that clinicians must consider a wider range of clinical and functional
740 outcomes as well as interventions for people with PEs that go beyond strategies for
741 preventing transition to psychotic disorders. Our systematic review and meta-analysis suggest
742 that, despite its limited effectiveness in preventing transitions, CBT may be useful to reduce
743 the distress associated with PEs and cost-effective in comparison with treatment as usual.
744 However, the scarcity of studies focusing on remission from PEs and improvement of other
745 non-psychotic clinical and functional outcomes suggests a need for further research into
746 psychological treatments for this population.

747

748 **Declarations of interest**

749 SB, DF, PF, JG, JH, CK, LL, JP, DR, and ES declare no conflicts of interest. NG reports
750 grants from Wellcome Trust and personal fees from book publishers and training events
751 (outside the submitted work). PBJ reports personal fees from Lundbeck, Ricordati, and
752 Janssen scientific advisory boards (outside the submitted work). JS reports personal fees from
753 IESO Digital Health (outside the submitted work).

754

755 **Funding**

756 This paper presents independent research funded by the National Institute for Health
757 Research (NIHR) under its Programme Grants for Applied Research Programme (Reference
758 Number RP-PG-0616-20003). The views expressed are those of the authors and not
759 necessarily those of the NIHR or the Department of Health and Social Care.
760 The funding body had no role in study design; collection, analysis, or interpretation of data;
761 the writing of the report; or decision to submit the paper.

762

763 **Acknowledgements**

764 We are very grateful to medical librarians Veronica Phillips and Isla Kuhn at the University
765 of Cambridge Clinical School, who helped design the search strategies for this review. We
766 further thank the members of our Lived Experience Advisory Panel for their contributions to
767 the design of this research.

768

769 **Author contribution statement**

770 JP, PBJ, LL, DR, JG, JS, and ES conceived the review design. JP is the guarantor of the
771 review. ES, DR, CK, MH, JS, NG, JH, PF, DF, SB, PBJ, and JP contributed to the design of
772 the search strategy. ES, DR, JS, MH, SB and JP drafted the original manuscript draft. CK,
773 LL, JG, JH, PF, DF, NG, SB, and PBJ contributed to the review of manuscript drafts. All
774 authors approved the final version of the manuscript.

775

776 **Data availability**

777 Not applicable.

778

779

780

781

782

REFERENCES

783

784 Addington J, Addington D, Abidi S, et al. (2017) Canadian treatment guidelines for
785 individuals at clinical high risk of psychosis. *The Canadian Journal of Psychiatry* 62:
786 656-661.

787 Addington J, Epstein I, Liu L, et al. (2011) A randomized controlled trial of cognitive
788 behavioral therapy for individuals at clinical high risk of psychosis. *Schizophrenia*
789 *Research* 125: 54-61.

790 Alvarez-Jimenez M, Gleeson JF, Bendall S, et al. (2018) Enhancing social functioning in
791 young people at Ultra High Risk (UHR) for psychosis: A pilot study of a novel
792 strengths and mindfulness-based online social therapy. *Schizophrenia Research*.

793 Armijo-Olivo S, Stiles CR, Hagen NA, et al. (2012) Assessment of study quality for
794 systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool
795 and the Effective Public Health Practice Project Quality Assessment Tool:
796 methodological research. *Journal of evaluation in clinical practice* 18: 12-18.

797 Barlati S, Deste G, De Peri L, et al. (2013) Cognitive remediation in schizophrenia: current
798 status and future perspectives. *Schizophr Res Treatment* 2013: 156084.

799 Bechdolf A, Veith V, Schwarzer D, et al. (2005) Cognitive-behavioral therapy in the pre-
800 psychotic phase: an exploratory study. *Psychiatry research* 136: 251-255.

801 Bechdolf A, Wagner M, Veith V, et al. (2007) Randomized controlled multicentre trial of
802 cognitive behaviour therapy in the early initial prodromal state: effects on social
803 adjustment post treatment. *Early intervention in psychiatry* 1: 71-78.

804 Bradley J, Freeman D, Chadwick E, et al. (2017) Treating sleep problems in young people at
805 ultra-high risk of psychosis: a feasibility case series. *Behavioural and cognitive*
806 *psychotherapy* 46: 276-291.

807 Broome MR, Woolley JB, Johns LC, et al. (2005) Outreach and support in south London
808 (OASIS): implementation of a clinical service for prodromal psychosis and the at risk
809 mental state. *European Psychiatry* 20: 372-378.

810 Byrne RE and Morrison AP. (2014) Young people at risk of psychosis: their subjective
811 experiences of monitoring and cognitive behaviour therapy in the early detection and
812 intervention evaluation 2 trial. *Psychology and Psychotherapy: Theory, Research and*
813 *Practice* 87: 357-371.

814 Cannon TD, Cadenhead K, Cornblatt B, et al. (2008) Prediction of psychosis in youth at high
815 clinical risk: a multisite longitudinal study in North America. *Archives of general*
816 *psychiatry* 65: 28-37.

817 Cornblatt B, Lencz T and Obuchowski M. (2002) The schizophrenia prodrome: treatment and
818 high-risk perspectives. *Schizophrenia Research* 54: 177-186.

819 Davies C, Cipriani A, Ioannidis JPA, et al. (2018a) Lack of evidence to favor specific
820 preventive interventions in psychosis: a network meta-analysis. *World Psychiatry* 17:
821 196-209.

822 Davies C, Radua J, Cipriani A, et al. (2018b) Efficacy and Acceptability of Interventions for
823 Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of
824 Psychosis: A Network Meta-Analysis. *Frontiers in Psychiatry* 9.

825 Deeks JJ, Higgins JPT, Altman DG, et al. (2018) Chapter 10: Analysing data and undertaking
826 meta-analyses (Draft version 13 September 2018). In: Higgins J, Thomas J, Chandler
827 J, et al. (eds) *Cochrane Handbook for Systematic Reviews of Interventions*. London:
828 Cochrane.

829 Devoe DJ, Farris MS, Townes P, et al. (2019) Attenuated psychotic symptom interventions in
830 youth at risk of psychosis: A systematic review and meta-analysis. *Early intervention*
831 *in psychiatry* 13: 3-17.

832 Drummond MF and Jefferson TO. (1996) Guidelines for authors and peer reviewers of
833 economic submissions to the BMJ. The BMJ Economic Evaluation Working Party.
834 *BMJ: British medical journal* 313: 275.

835 Drummond MF, Sculpher MJ, Claxton K, et al. (2015) *Methods for the economic evaluation*
836 *of health care programmes*: Oxford university press.

837 Early Psychosis Guidelines Writing Group and EPPIC National Support Program. (2016)
838 *Australian Clinical Guidelines for Early Psychosis, 2nd edition update*.

839 Evans C, Forrester A, Jarrett M, et al. (2017) Early detection and early intervention in prison:
840 Improving outcomes and reducing prison returns. *The Journal of Forensic Psychiatry*
841 *& Psychology* 28: 91-107.

842 Fernández-Castilla B, Beretvas SN, Onghena P, et al. (2019) Multilevel Models in Meta-
843 Analysis: A Systematic Review of Their Application and Suggestions. ZPID (Leibniz
844 Institute for Psychology Information).

845 Flach C, French P, Dunn G, et al. (2015) Components of therapy as mechanisms of change in
846 cognitive therapy for people at risk of psychosis: analysis of the EDIE-2 trial. *The*
847 *British Journal of Psychiatry* 207: 123-129.

848 Fowler D, Hodgekins J, French P, et al. (2018) Social recovery therapy in combination with
849 early intervention services for enhancement of social recovery in patients with first-
850 episode psychosis (SUPEREDEN3): a single-blind, randomised controlled trial. *The*
851 *Lancet Psychiatry* 5: 41-50.

852 Fusar-Poli P, Nelson B, Valmaggia L, et al. (2012) Comorbid depressive and anxiety
853 disorders in 509 individuals with an at-risk mental state: impact on psychopathology
854 and transition to psychosis. *Schizophrenia Bulletin* 40: 120-131.

855 Granö N, Karjalainen M, Suominen K, et al. (2011) Poor functioning ability is associated
856 with high risk of developing psychosis in adolescents. *Nordic journal of psychiatry*
857 65: 16-21.

858 Higgins JPT and Green S. (2011) *Cochrane handbook for systematic reviews of*
859 *interventions*: John Wiley & Sons.

860 Hui C, Morcillo C, Russo DA, et al. (2013) Psychiatric morbidity, functioning and quality of
861 life in young people at clinical high risk for psychosis. *Schizophrenia Research* 148:
862 175-180.

863 Hutton P, Bowe S, Parker S, et al. (2011) Prevalence of suicide risk factors in people at ultra-
864 high risk of developing psychosis: a service audit. *Early intervention in psychiatry* 5:
865 375-380.

866 Hutton P and Taylor PJ. (2014) Cognitive behavioural therapy for psychosis prevention: a
867 systematic review and meta-analysis. *Psychological medicine* 44: 449-468.

868 Ising HK, Kraan TC, Rietdijk J, et al. (2016) Four-year follow-up of cognitive behavioral
869 therapy in persons at ultra-high risk for developing psychosis: the Dutch early
870 detection intervention evaluation (EDIE-NL) trial. *Schizophrenia Bulletin* 42: 1243-
871 1252.

872 Ising HK, Lokkerbol J, Rietdijk J, et al. (2017) Four-year cost-effectiveness of cognitive
873 behavior therapy for preventing first-episode psychosis: the Dutch Early Detection
874 Intervention Evaluation (EDIE-NL) trial. *Schizophrenia Bulletin* 43: 365-374.

875 Ising HK, Smit F, Veling W, et al. (2015) Cost-effectiveness of preventing first-episode
876 psychosis in ultra-high-risk subjects: multi-centre randomized controlled trial.
877 *Psychological medicine* 45: 1435-1446.

878 Kelleher I, Lynch F, Harley M, et al. (2012) Psychotic symptoms in adolescence index risk
879 for suicidal behavior: findings from 2 population-based case-control clinical interview
880 studies. *Archives of general psychiatry* 69: 1277-1283.

881 Klosterkötter J, Hellmich M, Steinmeyer EM, et al. (2001) Diagnosing schizophrenia in the
882 initial prodromal phase. *Archives of general psychiatry* 58: 158-164.

883 Kommescher M, Wagner M, Pützfeld V, et al. (2016) Coping as a predictor of treatment
884 outcome in people at clinical high risk of psychosis. *Early intervention in psychiatry*
885 10: 17-27.

886 Langer ÁI, Cangas AJ and Gallego J. (2010) Mindfulness-based intervention on distressing
887 hallucination-like experiences in a nonclinical sample. *Behaviour Change* 27: 176-
888 183.

889 Law H and Morrison AP. (2014) Recovery in psychosis: a Delphi study with experts by
890 experience. *Schizophrenia Bulletin* 40: 1347-1355.

891 Liberati A, Altman DG, Tetzlaff J, et al. (2009) The PRISMA statement for reporting
892 systematic reviews and meta-analyses of studies that evaluate health care
893 interventions: explanation and elaboration. *PLoS medicine* 6: e1000100.

894 Marshall M and Rathbone J. (2011) Early intervention for psychosis. *Cochrane Database of*
895 *Systematic Reviews*.

896 Matsumoto K, Ohmuro N, Tsujino N, et al. (2018) Open-label study of cognitive behavioural
897 therapy for individuals with at-risk mental state: Feasibility in the Japanese clinical
898 setting. *Early intervention in psychiatry*.

899 McGorry PD, Hartmann JA, Spooner R, et al. (2018) Beyond the “at risk mental state”
900 concept: transitioning to transdiagnostic psychiatry. *World Psychiatry* 17: 133-142.

901 McGorry PD, Nelson B, Markulev C, et al. (2017) Effect of ω -3 polyunsaturated fatty acids
902 in young people at ultrahigh risk for psychotic disorders: the NEURAPRO
903 randomized clinical trial. *JAMA psychiatry* 74: 19-27.

904 McGorry PD, Nelson B, Phillips LJ, et al. (2013) Randomized controlled trial of
905 interventions for young people at ultra-high risk of psychosis: twelve-month outcome.
906 *The Journal of clinical psychiatry*.

907 McGorry PD, Yung AR, Phillips LJ, et al. (2002) Randomized controlled trial of
908 interventions designed to reduce the risk of progression to first-episode psychosis in a
909 clinical sample with subthreshold symptoms. *Archives of general psychiatry* 59: 921-
910 928.

911 Miller TJ, McGlashan TH, Rosen JL, et al. (2003) Prodromal assessment with the structured
912 interview for prodromal syndromes and the scale of prodromal symptoms: predictive
913 validity, interrater reliability, and training to reliability. *Schizophrenia Bulletin* 29:
914 703-715.

915 Miller TJ, McGlashan TH, Rosen JL, et al. (2002) Prospective diagnosis of the initial
916 prodrome for schizophrenia based on the Structured Interview for Prodromal
917 Syndromes: preliminary evidence of interrater reliability and predictive validity.
918 *American Journal of Psychiatry* 159: 863-865.

919 Morrison AP and Barratt S. (2009) What are the components of CBT for psychosis? A Delphi
920 study. *Schizophrenia Bulletin* 36: 136-142.

921 Morrison AP, French P, Stewart SLK, et al. (2012) Early detection and intervention
922 evaluation for people at risk of psychosis: multisite randomised controlled trial. *Bmj*
923 344: e2233.

924 Morrison AP, French P, Walford L, et al. (2004) Cognitive therapy for the prevention of
925 psychosis in people at ultra-high risk: randomised controlled trial. *The British Journal*
926 *of Psychiatry* 185: 291-297.

927 National Institute for Health and Care Excellence. (2014a) *Psychosis and schizophrenia in*
928 *adults: prevention and management: Clinical guideline [CG178]* Available at:
929 https://www.nice.org.uk/guidance/cg178/chapter/recommendations#ftn.footnote_2.

930 National Institute for Health and Care Excellence. (2014b) Psychosis and schizophrenia in
931 adults: prevention and management. Guideline CG178. In: National Institute for
932 Health and Care Excellence (ed). London.

933 Nelson B, Amminger GP and McGorry PD. (2018a) Recent Meta-Analyses in the Clinical
934 High Risk for Psychosis Population: Clinical Interpretation of Findings and
935 Suggestions for Future Research. *Frontiers in Psychiatry* 9.

936 Nelson B, Amminger GP, Yuen HP, et al. (2018b) NEURAPRO: a multi-centre RCT of
937 omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk
938 of psychotic disorders—medium-term follow-up and clinical course. *NPJ*
939 *schizophrenia* 4.

940 Nelson B, Sass LA and Škodlar B. (2009) The phenomenological model of psychotic
941 vulnerability and its possible implications for psychological interventions in the ultra-
942 high risk ('prodromal') population. *Psychopathology* 42: 283-292.

943 O'Brien MP, Miklowitz DJ and Cannon TD. (2015) Decreases in perceived maternal
944 criticism predict improvement in subthreshold psychotic symptoms in a randomized
945 trial of family-focused therapy for individuals at clinical high risk for psychosis.
946 *Journal of Family Psychology* 29: 945.

947 Okuzawa N, Kline E, Fuertes J, et al. (2014) Psychotherapy for adolescents and young adults
948 at high risk for psychosis: a systematic review. *Early intervention in psychiatry* 8:
949 307-322.

950 Perez J, Russo DA, Stochl J, et al. (2017) Common mental disorder including psychotic
951 experiences: Trailblazing a new recovery pathway within the Improving Access to
952 Psychological Therapies programme in England. *Early intervention in psychiatry*.

953 Perlis RH, Uher R, Ostacher M, et al. (2011) Association between bipolar spectrum features
954 and treatment outcomes in outpatients with major depressive disorder. *Archives of*
955 *general psychiatry* 68: 351-360.

956 Phillips LJ, Cotton S, Mihalopoulos C, et al. (2009) Cost implications of specific and non-
957 specific treatment for young persons at ultra high risk of developing a first episode of
958 psychosis. *Early intervention in psychiatry* 3: 28-34.

959 Phillips LJ, McGorry PD, Yuen HP, et al. (2007) Medium term follow-up of a randomized
960 controlled trial of interventions for young people at ultra high risk of psychosis.
961 *Schizophrenia Research* 96: 25-33.

962 Piskulic D, Barbato M, Liu L, et al. (2015) Pilot study of cognitive remediation therapy on
963 cognition in young people at clinical high risk of psychosis. *Psychiatry research* 225:
964 93-98.

965 Popay J, Roberts H, Sowden A, et al. (2006) Guidance on the conduct of narrative synthesis
966 in systematic reviews. *A product from the ESRC methods programme Version 1*: b92.

967 Rietdijk J, Dragt S, Klaassen R, et al. (2010) A single blind randomized controlled trial of
968 cognitive behavioural therapy in a help-seeking population with an At Risk Mental
969 State for psychosis: the Dutch Early Detection and Intervention Evaluation (EDIE-
970 NL) trial. *Trials* 11: 30.

971 Ruhrmann S, Bechdolf A, Kühn K-U, et al. (2007) Acute effects of treatment for prodromal
972 symptoms for people putatively in a late initial prodromal state of psychosis. *The*
973 *British Journal of Psychiatry* 191: s88-s95.

974 Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, et al. (2015) EPA guidance on the early
975 intervention in clinical high risk states of psychoses. *European Psychiatry* 30: 388-
976 404.

977 Shi J, Wang L, Yao Y, et al. (2017) Systemic Therapy for Youth at Clinical High Risk for
978 Psychosis: a Pilot Study. *Frontiers in psychiatry* 8: 211.

979 Sonesson E, Russo D, Knight C, et al. (2019) Psychological interventions for people with
980 psychotic experiences: protocol for a systematic review and meta-analysis. *Systematic*
981 *reviews* 8: 124.

982 Stafford E, Hides L and Kavanagh DJ. (2015) The acceptability, usability and short-term
983 outcomes of Get Real: A web-based program for psychotic-like experiences (PLEs).
984 *Internet Interventions* 2: 266-271.

985 Stafford MR, Jackson H, Mayo-Wilson E, et al. (2013) Early interventions to prevent
986 psychosis: systematic review and meta-analysis. *Bmj* 346: f185.

987 Stain HJ, Bucci S, Baker AL, et al. (2016) A randomised controlled trial of cognitive
988 behaviour therapy versus non-directive reflective listening for young people at ultra
989 high risk of developing psychosis: The detection and evaluation of psychological
990 therapy (DEPTH) trial. *Schizophrenia Research* 176: 212-219.

991 Valiji Bharmal A, Goodyer I and Wilkinson P. (2015) Are psychotic features in adolescents
992 with depression a predictor of severity? *Congress of Psychiatry Medforum*. Wisla,
993 Poland.

994 van der Gaag M, Nieman DH, Rietdijk J, et al. (2012) Cognitive behavioral therapy for
995 subjects at ultrahigh risk for developing psychosis: a randomized controlled clinical
996 trial. *Schizophrenia Bulletin* 38: 1180-1188.

997 van der Gaag M, Smit F, Bechdolf A, et al. (2013) Preventing a first episode of psychosis:
998 meta-analysis of randomized controlled prevention trials of 12 month and longer-term
999 follow-ups. *Schizophrenia Research* 149: 56-62.

1000 Viechtbauer W. (2010) Conducting meta-analyses in R with the metafor package. *J Stat*
1001 *Softw* 36: 1-48.

1002 Wigman JTW, Van Os J, Abidi L, et al. (2014) Subclinical psychotic experiences and bipolar
1003 spectrum features in depression: association with outcome of psychotherapy.
1004 *Psychological medicine* 44: 325-336.

1005 Yates K, Lång U, Cederlöf M, et al. (2019) Association of Psychotic Experiences With
1006 Subsequent Risk of Suicidal Ideation, Suicide Attempts, and Suicide Deaths: A
1007 Systematic Review and Meta-analysis of Longitudinal Population Studies. *JAMA*
1008 *psychiatry* 76: 180-189.

1009 Yung AR, McGorry PD, McFarlane CA, et al. (1996) Monitoring and care of young people at
1010 incipient risk of psychosis. *Schizophrenia Bulletin* 22: 283-303.

- 1011 Yung AR, Pan Yuen H, McGorry PD, et al. (2005) Mapping the onset of psychosis: the
1012 comprehensive assessment of at-risk mental states. *Australian & New Zealand*
1013 *Journal of Psychiatry* 39: 964-971.
- 1014 Yung AR, Phillips LJ, Yuen HP, et al. (2003) Psychosis prediction: 12-month follow up of a
1015 high-risk (“prodromal”) group. *Schizophrenia Research* 60: 21-32.
- 1016